NCT03033498 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

June 8, 2019

Study Completion Date

June 8, 2019

Conditions

Parkinson's Disease (PD)

Interventions

DRUG

ABBV-951

ABBV-951 administered by subcutaneous infusion.

Trial Locations (7)

Parexel Baltimore /ID# 169255, Baltimore

Carolina Phase I, LLC /ID# 166034, Raleigh

Bioclinica Research - Orlando /ID# 169687, Orlando

University of Kentucky Chandler Medical Center /ID# 169086, Lexington

Acpru /Id# 154976, Grayslake

Glendale Adventist Medical Ctr /ID# 166512, Glendale

QUEST Research Institute /ID# 166035, Farmington Hills